Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.0K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

LIF/LIFR Signaling in Gastric Cancer: A Double-Edged Sword in Tumor Progression and Therapeutic Resistance.

Cancer medicine·2025
Same author

Racial/ethnic disparities in hepatocellular carcinoma treatment and survival: an analysis of the California Cancer Registry.

Cancer treatment and research communications·2025
Same author

Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same author

Liver Resection for Gastroenteropancreatic Neuroendocrine Tumors with Extrahepatic Disease.

Journal of clinical medicine·2024
Same author

Safety of pressurized intraperitoneal aerosolized chemotherapy in biliary cancer patients with peritoneal metastases.

Future oncology (London, England)·2024
Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Sep 20, 2025

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
04:50

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

415

Updates in Biliary Tract Cancers.

Daneng Li1, Ya-Han Zhang1, Christiana J Crook1

  • 1Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA 91010, USA.

Cancers
|June 10, 2022
PubMed
Summary
This summary is machine-generated.

Biliary tract cancers (BTCs) are diverse malignant tumors originating in the bile ducts. Understanding their heterogeneity is key to developing targeted therapies for these challenging diseases.

More Related Videos

Robotic Taj Mahal Hepatectomy for Hilar Cholangiocarcinoma
09:19

Robotic Taj Mahal Hepatectomy for Hilar Cholangiocarcinoma

Published on: July 14, 2022

3.6K
Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction
07:44

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction

Published on: March 25, 2022

6.0K

Related Experiment Videos

Last Updated: Sep 20, 2025

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
04:50

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

415
Robotic Taj Mahal Hepatectomy for Hilar Cholangiocarcinoma
09:19

Robotic Taj Mahal Hepatectomy for Hilar Cholangiocarcinoma

Published on: July 14, 2022

3.6K
Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction
07:44

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction

Published on: March 25, 2022

6.0K

Area of Science:

  • Oncology
  • Gastroenterology
  • Pathology

Background:

  • Biliary tract cancers (BTCs) encompass a spectrum of malignancies including cholangiocarcinoma and gallbladder cancer.
  • These cancers arise from the epithelial lining of the bile ducts and gallbladder, presenting significant diagnostic and therapeutic challenges.

Discussion:

  • The heterogeneity of BTCs necessitates a deeper understanding of their molecular and cellular underpinnings.
  • Investigating the diverse origins and progression pathways is crucial for effective treatment strategies.

Key Insights:

  • BTCs exhibit significant variability in their histological and molecular features.
  • Identifying distinct subtypes of biliary tract cancers can inform personalized treatment approaches.

Outlook:

  • Future research should focus on characterizing BTC heterogeneity to develop novel targeted therapies.
  • Advancements in diagnostics and treatment modalities are essential for improving patient outcomes in biliary tract cancers.